A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor

Inclusion Criteria:

- Subject must have either

• Relapsed or refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (for
Waves 2 or 3)

- Subject has evaluable disease and requires treatment in the opinion of the
investigator.

- Subject must have relapsed following or be refractory to ≥ 1 standard treatments such
as fludarabine based regimens (F, FC, FR, FCR), alkylator (chlorambucil,
bendamustine) based regimens, or Bruton's Tyrosine Kinase inhibitor (Ibrutinib).

Or

• Relapsed or refractory indolent Non-Hodgkin Lymphoma or aggressive Non-Hodgkin Lymphoma
(for Waves 1, 2, or 3, unless otherwise indicated)

- Subject must have histologically documented diagnosis of a Follicular Lymphoma or
Marginal Zone Lymphoma.

- Subject must have histologically documented diagnosis of a Diffuse Large B-cell
Lymphoma (excluding Richter's Transformation), Non-cutaneous T-Cell Lymphoma, or
Mantle Cell Lymphoma (MCL) (MCL Wave 3 only)

- Subject has evaluable disease and requires treatment in the opinion of the
investigator.

- Subject must have relapsed following or be refractory to ≥ 1 standard treatments such
as R-CHOP, R-CVP, bendamustine, lenalidomide-rituximab, or fludarabine-based
regimens.

- Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of
less than or equal to 2.

- Subject must have adequate bone marrow independent of growth factor support per
local laboratory reference range at Screening.

- Subject must have adequate coagulation, renal, and hepatic function, per
laboratory reference range at Screening.

- NHL subjects who have a history of an autologous stem cell transplant (e.g.,
bone marrow) must be > 6 months post-transplant (prior to the first dose of
study drug) and must not require any growth factor support.

Exclusion Criteria:

- Subject has been previously treated with a Bcl-2 or PI3K inhibitor.

- Subject is a candidate to receive another second-line therapy approved for usage by
the local Health Authority.

- Subject is appropriate for a stem cell transplant or has undergone an allogeneic stem
cell transplant.

- Subject has received any of the following within 14 days or 5 drug half-lives
(whichever is shortest) prior to the first dose of duvelisib or venetoclax, or has
not recovered to less than Grade 2 clinically significant adverse
effect(s)/toxicity(s) of the previous therapy:

- Any anti-cancer therapy including chemotherapy or radiotherapy;

- Investigational therapy, including targeted small molecule agents.

- Subject has received biologic agents (e.g., monoclonal antibodies) for
anti-neoplastic treatment within 30 days prior to first dose of duvelisib or
venetoclax.

- Subject has received live or live attenuated vaccines within 6 weeks prior to first
dose of duvelisib or venetoclax.

- Subject has received the following within 7 days prior to the first dose of duvelisib
or venetoclax:

- Steroid therapy for anti-neoplastic treatment;

- Strong and Moderate CYP3A inhibitors;

- Strong and Moderate CYP3A inducers;

- Chronic immunosuppressants, other than corticosteroids given at daily dose < 20
mg prednisone equivalent for ITP or AIHA.